NEW YORK (GenomeWeb News) – RNA-based testing firm HTG Molecular Diagnostics today said it has initially closed its Series E preferred stock offering.

Through a spokesperson, HTG and its investors declined to disclose the amount of the Series E round. Existing investors Novo Ventures, SROne, Merck Capital Ventures, and Fletcher Spaght participated in the round.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.